Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) and Ardelyx (NASDAQ:ARDX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.
Volatility and Risk
Kiora Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
Institutional and Insider Ownership
77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Kiora Pharmaceuticals and Ardelyx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kiora Pharmaceuticals | N/A | -82.06% | -55.72% |
| Ardelyx | -11.85% | -35.30% | -10.23% |
Analyst Ratings
This is a breakdown of current ratings and target prices for Kiora Pharmaceuticals and Ardelyx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiora Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Ardelyx | 1 | 1 | 8 | 2 | 2.92 |
Ardelyx has a consensus target price of $13.60, indicating a potential upside of 340.13%. Given Ardelyx’s stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Kiora Pharmaceuticals.
Valuation and Earnings
This table compares Kiora Pharmaceuticals and Ardelyx”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiora Pharmaceuticals | $16.02 million | 0.34 | -$10.84 million | ($2.51) | -0.49 |
| Ardelyx | $407.32 million | 1.91 | -$61.60 million | ($0.22) | -14.05 |
Kiora Pharmaceuticals has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Ardelyx beats Kiora Pharmaceuticals on 11 of the 14 factors compared between the two stocks.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for retinal and other eye diseases. Its research centers on therapies intended to address conditions with limited treatment options. The company’s pipeline includes KIO-301, an investigational photoswitch designed to restore light sensitivity in people with retinitis pigmentosa and other inherited retinal degenerative diseases. Kiora is also developing KIO-101, an investigational therapy for inflammatory eye diseases, including non-infectious uveitis.
About Ardelyx
Ardelyx, Inc. is a biopharmaceutical company that develops and commercializes medicines for kidney and gastrointestinal diseases. Founded in 2007, the company has focused on treatments that work in the gastrointestinal tract, including therapies based on tenapanor. Ardelyx markets IBSRELA (tenapanor) in the United States for adults with irritable bowel syndrome with constipation. It also markets XPHOZAH (tenapanor) to help control serum phosphorus in adults with chronic kidney disease who are on dialysis.
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
